Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN II 15% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
Amino acids serve as substrates for protein synthesis and intermediary metabolism; dextrose provides caloric replacement; electrolytes maintain acid-base and electrolyte balance.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day administered as a continuous or intermittent infusion, providing 4.25% amino acids and 5% dextrose. Rate adjusted based on metabolic needs and tolerance.
None Documented
None Documented
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Not applicable as a composite; amino acids have varying half-lives (minutes). Dextrose: glucose half-life ~1.5-2.5 hours in healthy individuals. Clinical context: continuous infusion maintains steady state.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Amino acids: renal elimination of unmodified amino acids is minimal (<5%); most nitrogen is excreted as urea via kidneys. Dextrose: fully metabolized, negligible renal excretion of intact glucose. Electrolytes: renally excreted.
Category C
Category C
Amino Acid Solution
Amino Acid Solution